MARKET

RGNX

RGNX

Regenxbio
NASDAQ
16.04
+0.14
+0.88%
After Hours: 16.04 0 0.00% 16:03 04/24 EDT
OPEN
15.96
PREV CLOSE
15.90
HIGH
16.39
LOW
15.60
VOLUME
345.64K
TURNOVER
0
52 WEEK HIGH
28.80
52 WEEK LOW
11.83
MARKET CAP
786.65M
P/E (TTM)
-2.6623
1D
5D
1M
3M
1Y
5Y
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 1d ago
Weekly Report: what happened at RGNX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at RGNX last week (0408-0412)?
Weekly Report · 04/15 09:25
Institutional owners may consider drastic measures as REGENXBIO Inc.'s (NASDAQ:RGNX) recent US$53m drop adds to long-term losses
Institutional investors own over 50% of REGENXBIO Inc. (NASDAQ:RGNX) The top 6 shareholders of the company own 53% of the stock. In the last year, the company has lost 4.6% of its market value. With a 72% stake, institutions have significant influence over the company's share price. RegenxBIO has a high level of insider ownership, but the company is not in sync with other shareholders. We look at the ownership structure of RegenXBIo Inc. To see how the company operates.
Simply Wall St · 04/14 12:48
REGENXBIO Is Maintained at Buy by Stifel
Dow Jones · 04/12 16:03
Where Regenxbio Stands With Analysts
Regenxbio is a biotechnology company developing a gene therapy. The company has an average price target of $38.22. The 12-month price target is up 1.25% from the previous average of $37.75. Regenxbio has 9 analysts' ratings ranging from bullish to bearish.
Benzinga · 04/12 16:01
Commit To Purchase REGENXBIO At $7.50, Earn 10.1% Annualized Using Options
NASDAQ · 04/09 15:33
Weekly Report: what happened at RGNX last week (0401-0405)?
Weekly Report · 04/08 09:26
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.